

Supporting Diversity in Clinical Trial Recruitment



Our unique relationships with 100+ traditional and non-traditional recruitment partners enable us to connect sponsors with diverse populations that may otherwise be unreachable using conventional approaches.

Here's how the Citeline Connect Recruitment Collective partnership network drives study awareness and participation globally.

Phase II-III Alzheimer's Disease Trial (ongoing)

Oct. 2022-present

34%

of Citeline Connect qualified referrals in screening identify as a minority

7

recruitment partners supported the enrollment of diverse study participants



Recruitment of diverse patients spanned across **19 states**

Phase II Atopic Dermatitis Trial

Oct. 2022 -Feb. 2023

64%

of Citeline Connect qualified referrals identify as a minority

5

recruitment partners supported the enrollment of diverse study participants

Recruitment of diverse patients spanned across **2 countries**



Phase III CMV Trial (ongoing)

Sept. 2022 -present

Contributing to **44%** of US enrollment; **41%** of Citeline Connect qualified referrals identify as a minority

15

recruitment partners supported the enrollment of diverse study participants



Recruitment of diverse patients spanned across **4 countries**

Phase III RSV Trial

Sept. 2022 -Dec. 2023

18% conversion rate

23,000+ referrals in 4 months with **28%** diversity

9

recruitment partners supported the enrollment of diverse study participants

Recruitment of diverse patients spanned across **2 countries**



Phase III COVID-19 Trial

Sept.-Oct. 2021

Doubled overall enrollment and increased diversity from

24% to 37%

14

recruitment partners supported the enrollment of diverse study participants



Recruitment of diverse patients spanned across **100 sites and 31 states** in the US



Tap into the Citeline network of 100+ recruitment partners to drive study awareness and participation among patient populations representative of the real world.